Mitochondria: the powerhouse of the cell—but the fuel behind gout flares? #ACR24 @RheumNow https://t.co/lV4dovLV18

• https://twitter.com/tuhina_neogi/status/1858614167109816655

#CRISPR reviewed in 👇 #fibroblasts Found deletion of certain genes Ex JIA had marked change in expression Yr in Preview ACR24 @RheumNow @ACRheum Dr Chris Ritchlin 👏 https://t.co/jnmtk1eXGp

• https://x.com/Janetbirdope/status/1858895113872707672/photo/1

Mortality Risk After Stopping Glucocorticosteroids (GC) in RA. In a study of 28,078 RA patients: Mortality risk from CVD ↑ 7.5%/year of GC use; ↓ 1.3%/year after stopping. Mortality risk from infections ↑ 6.8%/year of GC use; ↓ 4.9%/year after stopping. Risks normalize 1.5–10… https://t.co/i6cKet1EEV https://t.co/ClMjIly20E

• https://x.com/i/web/status/1858895508363776345
• https://x.com/synovialjoints/status/1858895508363776345/photo/1

Did you know? 🤔 Capillaroscopy is performed on the nailfold because it is the area where the capillaries are fully visualized compared to the skin where capillary tips are only seen. This capillaroscopy session with Dr. Cutolo is so high yield I'd say! 🤓 @RheumNow #ACR24 https://t.co/8AN7RXUDrM

• https://x.com/RHEUMarampa/status/1858897030413762965/photo/1

#Poorer responses to #Rx in #Females vs #males Sex hormone and pathway differences explained 👇 Biological differences F start worse in disease activity F May have ⬇️ response to #Rx Yr in Preview C Ritchlin @lihi_eder’s PsA work quoted ACR24 @RheumNow @ACRheum @ACRBest https://t.co/EWoCvzOLiL

• https://x.com/Janetbirdope/status/1858898119162843619/photo/1

VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA. RA patients vaccinated with PCV13 1 month before MTX initiation had higher responder rates at 1 month: 88% (ELISA) vs. 75% 96% (OPA) vs. 88% At 12 months, responses remained stronger in… https://t.co/bSbIazsRtG

• https://x.com/i/web/status/1858899283182821530

Hydralazine - known culprit of drug-induced AAV How does hydral (H) AAV differ from primary (1) AAV? 💥 High dual positivity MPO/PR3 💥 DAH / pleuritis more common in H-AAV 💥 ENT, constitutional, nervous, ILD in 1-AAV 💥 More 6mo remission in H-AAV @rheumnow #ACR24 Abst 2496

Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr

• Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Ear…
• https://x.com/RichardPAConway/status/1858903813266305537/photo/1

Severe thrombocytopenia (TP) is rare but linked to major organ involvement and poor prognosis in #SLE. Data from the RISE registry shows TP in 9.3% of SLE patients, with higher prevalence in males, African-Americans+ those with multiple comorbidities. #ACR24 @RheumNow abst#2680

In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity. Mechanism? NAC reduces rapamycin (mTOR) activation. Common AEs: nausea, vomiting @RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP

• https://x.com/RHEUMarampa/status/1858907159624339570/photo/1
• https://x.com/RHEUMarampa/status/1858907159624339570/photo/1

Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs

• Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Met…
• https://x.com/RichardPAConway/status/1858908090919514625/photo/1

In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II #ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe

• https://x.com/JihaRheum/status/1858908090973786126/photo/1

Difficult to Manage Axial Spondyloarthritis Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. #ACR24 https://t.co/5i5QtJJm16 https://t.co/c4bllA8ngJ

• Difficult to Manage Axial Spondyloarthritis | RheumNow

RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.

SELECT-GCA suggests JAKis may be the new kid on the block Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY

• SELECT-GCA suggests JAKis may be the new kid on the block | RheumNow